Fan Hui, Pan QingRong, Xu Yuan, Yang XinChun
Arq Bras Endocrinol Metabol. 2013 Dec;57(9):702-8. doi: 10.1590/s0004-27302013000900005.
To investigate the effects of exenatide on blood glucose, body weight and hepatic enzymes in patients with type 2 diabetes mellitus (T2DM) and concomitant non-alcoholic fatty liver disease (NAFLD).
One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group. Patients were treated with exenatide and metformin, respectively, for 12 weeks.
After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups. BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD.
探讨艾塞那肽对2型糖尿病（T2DM）合并非酒精性脂肪性肝病（NAFLD）患者血糖、体重及肝酶的影响。
117例T2DM合并NAFLD患者随机分为艾塞那肽组和二甲双胍组。患者分别接受艾塞那肽和二甲双胍治疗12周。
治疗12周后，两组患者体重、体重指数（BMI）、腰臀比、糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2小时血糖（2-h PPG）、谷丙转氨酶（ALT）、谷草转氨酶（AST）、γ-谷氨酰转肽酶（γ-GT）和超敏C反应蛋白（hs-CRP）均显著降低，AST/ALT比值和脂联素均显著升高。艾塞那肽组的BMI、腰臀比、2-h PPG、ALT、AST、γ-GT和hs-CRP显著低于二甲双胍组，AST/ALT比值和脂联素显著高于二甲双胍组。
与二甲双胍相比，艾塞那肽能更好地控制血糖，减轻体重，改善肝酶，减轻T2DM合并NAFLD患者的NAFLD。
